All News

AAO-HNS Continues Advocacy on Balloon Ostial Dilation for Treatment of Chronic Rhinosinusitis (2/5/2020)

AAO-HNS Continues Advocacy on Balloon Ostial Dilation for Treatment of Chronic Rhinosinusitis (2/5/2020)

On February 5, the AAO-HNS sent comments to Blue Cross Blue Shield’s Federal Employee Program (BCBS FEP) opposing their medical policy designating balloon ostial dilation (BSOD) as experimental/investigational. The comment letter highlights the AAO-HNS Position Statement and Clinical Consensus Statement on BSOD, as well as provides extensive literature support demonstrating the procedure is consistent with the standard of care.

AAO-HNSF 2024 Annual Meeting & OTO EXPO Registration Opens Mid-MayLearn More